Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karp

Showing results (291-300 of 3,976) with videos related to

Pageof 398
Sort By:
Journal of the American Dental Association (1939)|June 3, 2006
Dental treatment of patients with long QT syndromeJeffrey M Karp, Arthur J Moss
Cancer Investigation|September 21, 2007
Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignanciesJudith E Karp, Jeffrey E Lancet
Proceedings of the National Academy of Sciences of the United States of America|July 15, 2004
MotifPrototyper: a Bayesian profile model for motif familiesEric P Xing, Richard M Karp
Proteomics|December 24, 2008
Investigating sample pooling strategies for DIGE experiments to address biological variabilityNatasha A Karp, Kathryn S Lilley
Science Signaling|December 26, 2008
Untangling the complex web of IL-4- and IL-13-mediated signaling pathwaysMarsha Wills-Karp, Fred D Finkelman
Clinical Lymphoma & Myeloma|September 26, 2009
What are the endpoints of therapy for acute leukemias? Old definitions and new challengesB Douglas Smith, Judith E Karp
Biologics : Targets & Therapy|August 27, 2009
Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemiaJudith E Karp, Jeffrey E Lancet
Current Oncology Reports|August 15, 2009
New agents in acute myeloid leukemia: beyond cytarabine and anthracyclinesAmir T Fathi, Judith E Karp
The Journal of Experimental Medicine|March 14, 2012
Non-canonical alternatives: what a macrophage is 4Christopher L Karp, Peter J Murray
Nature Reviews. Rheumatology|December 4, 2013
Autoantibodies and SLE: the threshold for diseaseNancy J Olsen, David R Karp
Pageof 398

Showing results (291-300 of 3,976) with videos related to

Sort By:
Pageof 398
Journal of the American Dental Association (1939)|June 3, 2006
Dental treatment of patients with long QT syndromeJeffrey M Karp, Arthur J Moss
Cancer Investigation|September 21, 2007
Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignanciesJudith E Karp, Jeffrey E Lancet
Proceedings of the National Academy of Sciences of the United States of America|July 15, 2004
MotifPrototyper: a Bayesian profile model for motif familiesEric P Xing, Richard M Karp
Proteomics|December 24, 2008
Investigating sample pooling strategies for DIGE experiments to address biological variabilityNatasha A Karp, Kathryn S Lilley
Science Signaling|December 26, 2008
Untangling the complex web of IL-4- and IL-13-mediated signaling pathwaysMarsha Wills-Karp, Fred D Finkelman
Clinical Lymphoma & Myeloma|September 26, 2009
What are the endpoints of therapy for acute leukemias? Old definitions and new challengesB Douglas Smith, Judith E Karp
Biologics : Targets & Therapy|August 27, 2009
Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemiaJudith E Karp, Jeffrey E Lancet
Current Oncology Reports|August 15, 2009
New agents in acute myeloid leukemia: beyond cytarabine and anthracyclinesAmir T Fathi, Judith E Karp
The Journal of Experimental Medicine|March 14, 2012
Non-canonical alternatives: what a macrophage is 4Christopher L Karp, Peter J Murray
Nature Reviews. Rheumatology|December 4, 2013
Autoantibodies and SLE: the threshold for diseaseNancy J Olsen, David R Karp
Pageof 398